Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients
- 15 March 1996
- Vol. 77 (6) , 1144-1148
- https://doi.org/10.1002/(sici)1097-0142(19960315)77:6<1144::aid-cncr21>3.0.co;2-0
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Inhibition of prostate cancer growth by estramustine and etoposideCancer, 1995
- Phase I?II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancerCancer Chemotherapy and Pharmacology, 1995
- Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.Journal of Clinical Oncology, 1994
- Oral etoposide in the treatment of hormone-refractory prostate cancerCancer, 1994
- Inhibition of Prostate Cancer Growth by Estramustineand Etoposide: Evidence For Interaction at the Nuclear MatrixJournal of Urology, 1993
- Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone-refractory prostatic cancer: A hoosier oncology group studyCancer, 1992
- EtoposideDrugs, 1990
- A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.Journal of Clinical Oncology, 1985
- A critical analysis of response criteria in patients with prostatic cancer treated with CIS-diamminedichloride platinum IICancer, 1979
- Prostatic CarcinomaNew England Journal of Medicine, 1979